Skip to main content

Table 1 Patient characteristics

From: Enhanced immune complex formation in the lungs of patients with dermatomyositis

 

DM-ILD group

IPF group

P value

Number

18

19

 

Age

54 (46–63)

65 (62–67)

0.001

Sex: male

6 (33%)

18 (95%)

0.001

RP-ILD or IPF-AE

9 (50%)

9 (47%)

 

Tissue collection method

   

 SLB

11 (61%)

10 (53%)

 

 Transplant

1 (6%)

0 (0%)

 

 Autopsy

6 (33%)

9 (47%)

 

Dx of IIMs

   

 DM

12 (67%)

–

 

 CADM

6 (33%)

–

 

Histological pattern

   

 DAD

11 (61%)

9 (47%)

 

 NSIP

6 (33%)

0 (0%)

 

 UIP

1 (6%)

10 (53%)

 

Treatment for autopsy and lung transplant cases

   

 Corticosteroid

7 (100%)

8 (89%)

 

 Calcineurin inhibitors

6 (86%)

2 (22%)

 

 Cyclophosphamide

5 (71%)

3 (33%)

 

Cause of death in autopsy cases

   

 Respiratory failure (including IPF-AE or RP-ILD)

6 (100%)

6 (67%)

 

 Lung cancer

0 (0%)

3 (33%)

 
  1. AE acute exacerbation; CADM clinical amyopathic dermatomyositis DAD diffuse alveolar damage; DM dermatomyositis; Dx diagnosis; IIMs idiopathic inflammatory myopathies; ILD interstitial lung disease; IPF idiopathic pulmonary fibrosis; NSIP nonspecific interstitial pneumonia; RP-ILD rapidly progressive interstitial lung disease; SLB surgical lung biopsy; UIP usual interstitial pneumonia